Olema Pharmaceuticals Inc (OLMA) is trading down at $7.02 (-0.43%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$4.32M | −$21.5M | −$71.5M | −$107.0M | −$105.0M | −$142.3M | −$178.7M |
| Net income | −$4.32M | −$22.1M | −$71.1M | −$104.8M | −$96.7M | −$129.5M | −$162.5M |
| EPS (diluted) | −$1.66 | −$3.42 | −$1.80 | −$2.62 | −$2.14 | −$2.20 | −$1.87 |
| Balance sheet | |||||||
| Cash and equivalents | $68.0K | $338.5M | $13.8M | $23.7M | $68.5M | $139.5M | $48.3M |
| Total assets | — | $342.7M | $295.9M | $215.6M | $276.9M | $451.0M | $533.4M |
| Total liabilities | — | $4.58M | $11.4M | $18.1M | $23.1M | $42.0M | $54.9M |
| Shareholders' equity | −$10.6M | $338.1M | $284.6M | $197.5M | $253.9M | $409.0M | $478.6M |
| Cash flow | |||||||
| Operating cash flow | −$3.08M | −$19.9M | −$50.7M | −$82.1M | −$83.7M | −$104.4M | −$146.7M |
| Capital expenditure | — | $56.0K | $1.57M | $363.0K | — | $159.0K | — |
| Free cash flow | — | −$19.9M | −$52.3M | −$82.4M | — | −$104.5M | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$37.6M | −$36.8M | −$34.9M | −$47.9M | −$45.9M | −$50.1M | −$58.0M | −$67.2M |
| Net income | −$34.6M | −$33.6M | −$30.4M | −$43.8M | −$42.2M | −$46.1M | −$53.1M | −$63.2M |
| EPS (diluted) | −$0.60 | −$0.50 | −$0.36 | −$0.51 | −$0.49 | −$0.51 | −$0.52 | −$0.61 |
| Balance sheet | ||||||||
| Cash and equivalents | $35.9M | $139.5M | $50.6M | $52.5M | $35.3M | $48.3M | $52.5M | $48.6M |
| Total assets | $230.2M | $451.0M | $409.6M | $382.0M | $352.5M | $533.4M | $530.6M | $486.6M |
| Total liabilities | $31.3M | $42.0M | $26.2M | $36.8M | $45.0M | $54.9M | $50.2M | $56.0M |
| Shareholders' equity | $198.9M | $409.0M | $383.5M | $345.2M | $307.5M | $478.6M | $480.5M | $430.6M |
| Cash flow | ||||||||
| Operating cash flow | −$27.0M | −$26.3M | −$44.0M | −$29.9M | −$34.5M | −$38.3M | −$46.0M | −$45.9M |
| Capital expenditure | $0 | $0 | — | — | $0 | — | — | — |
| Free cash flow | −$27.0M | −$26.3M | — | — | −$34.5M | — | — | — |
From Olema Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Olema Pharmaceuticals Inc in our feed yet.